Search results

82 items matching your search terms.
Filter the results.
Item type













New items since



Sort by relevance · date (newest first) · alphabetically
MBCN to hold annual Metastatic Breast Cancer Conference with UNC Lineberger in September
The Metastatic Breast Cancer Network (MBCN) is pleased to announce it will hold its 8th Annual National Conference September 19-21, 2014 in conjunction with the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina
Located in News
Breast cancer prevention drug benefit varies among at-risk women, study finds
After weighing the risk of serious side effects with the benefits of a breast cancer prevention drug, a study led by a University of North Carolina at Chapel Hill researcher found that the drug’s benefits outweighed risks for most, but not all women.
Located in News
Nichols awarded $200,000 Avon grant to study pregnancy-associated breast cancer
The 12th annual Avon Walk for Breast Cancer season concluded with the Charlotte Walk on October 26, raising $1.4 million to accelerate breast cancer research and improve access to screening, diagnosis, treatment and education. Hazel Nichols, PhD, assistant professor epidemiology at UNC Gillings School of Global Public Health is leading one of five teams in the Carolinas awarded a grant of $200,000 to support a study that will analyze data from 18 ongoing studies on pregnancy-associated breast cancer.
Located in News
Susan G. Komen for the Cure North Carolina Triangle to the Coast Affiliate awards $50,000 grant to UNC Lineberger Comprehensive Cancer Support Program
The Susan G. Komen North Carolina Triangle to the Coast (NCTC) has awarded a $50,000 grant to UNC Lineberger Comprehensive Cancer Support Program to fund a project aimed at improving access to comprehensive lymphedema care for breast cancer patients in central North Carolina.
Located in News
Dr. Lisa Carey authors editorial on neoadjuvant trials for breast cancer
Lisa Carey, MD, authored an editorial, titled “Neoadjuvant Trials of Human Epidermal Growth Factor Receptor 2 Targeting: How Many Drugs Do We Need?”
Located in News / 2012 News
UNC researchers find new genetic target for a different kind of cancer drug
Upstream of the proteins that cancer cells use to proliferate sits RBM4, a gene-splicing protein that UNC researcher Zefeng Wang, PhD, discovered is drastically reduced in human lung and breast cancer cells.
Located in News
Understanding multiple causes of racial disparities in breast cancer is essential
Racial disparities in the treatment and outcome of breast cancer patients arise from a combination of biological, social and financial causes. Understanding how these complex factors influence interactions between patients and the medical community is key to reducing the gaps in treatment and mortality between racial groups, according to researchers at the University of North Carolina.
Located in News
Solving Cancer’s Secrets: 5 Questions with Dr. Chuck Perou
Five questions for Chuck Perou, PhD, a UNC geneticist on the hunt for better treatments for the most deadly form of breast cancer
Located in News
Study quantifies false positives for yearly mammograms
Breast Cancer Surveillance Consortium also compares digital and film mammography
Located in News / 2011 News
Combination therapy for triple-negative breast cancer disappointing
CHAPEL HILL, N.C. – A recent clinical trial testing a combination therapy for basal-like (also known as triple-negative) breast cancer demonstrates that a combination of two drugs with promising preclinical results is not as effective as researchers had hoped.
Located in News / 2012 News